Your browser is no longer supported. Please, upgrade your browser.
ALPN Alpine Immune Sciences, Inc. monthly Stock Chart
Alpine Immune Sciences, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own0.50% Shs Outstand22.28M Perf Week25.13%
Market Cap213.94M Forward P/E- EPS next Y-0.65 Insider Trans10.04% Shs Float16.50M Perf Month27.08%
Income-27.70M PEG- EPS next Q-0.33 Inst Own52.90% Short Float0.15% Perf Quarter19.61%
Sales4.60M P/S46.51 EPS this Y13.50% Inst Trans90.48% Short Ratio0.54 Perf Half Y144.00%
Book/sh3.03 P/B3.22 EPS next Y55.20% ROA-30.80% Target Price- Perf Year222.11%
Cash/sh6.44 P/C1.52 EPS next 5Y- ROE-80.40% 52W Range2.05 - 15.00 Perf YTD154.17%
Dividend- P/FCF6.48 EPS past 5Y12.20% ROI-126.70% 52W High-34.93% Beta1.59
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low376.10% ATR0.55
Employees53 Current Ratio4.00 Sales Q/Q533.30% Oper. Margin- RSI (14)70.73 Volatility7.83% 6.29%
OptionableNo Debt/Eq0.15 EPS Q/Q55.40% Profit Margin- Rel Volume1.55 Prev Close9.84
ShortableYes LT Debt/Eq0.13 EarningsNov 12 AMC Payout- Avg Volume47.55K Price9.76
Recom1.40 SMA2020.97% SMA5018.50% SMA20051.60% Volume72,841 Change-0.81%
Aug-26-20Initiated Cowen Outperform
Nov-24-20 04:05PM  
Nov-16-20 04:05PM  
Nov-15-20 07:03AM  
Nov-12-20 04:05PM  
Nov-05-20 04:05PM  
Oct-28-20 06:32AM  
Sep-15-20 04:05PM  
Sep-08-20 04:05PM  
Aug-26-20 09:42AM  
Aug-11-20 04:05PM  
Aug-05-20 04:05PM  
Aug-04-20 04:05PM  
Jul-24-20 09:15AM  
Jul-22-20 06:45AM  
Jul-08-20 09:05AM  
Jun-25-20 12:09PM  
Jun-24-20 08:00AM  
Jun-19-20 11:27AM  
Jun-18-20 10:22AM  
Jun-15-20 08:00AM  
Jun-11-20 06:57AM  
Jun-10-20 03:44PM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-29-20 08:00AM  
May-26-20 04:05PM  
May-16-20 08:11AM  
May-14-20 04:01PM  
Apr-27-20 09:00AM  
Apr-20-20 04:05PM  
Apr-13-20 06:15AM  
Apr-07-20 07:06AM  
Mar-30-20 04:01PM  
Mar-18-20 07:15AM  
Mar-02-20 04:05PM  
Feb-25-20 04:02PM  
Jan-24-20 07:30AM  
Jan-14-20 06:17AM  
Jan-06-20 07:30AM  
Dec-22-19 01:52PM  
Dec-09-19 07:30AM  
Nov-26-19 07:30AM  
Nov-13-19 04:05PM  
Nov-12-19 07:30AM  
Nov-08-19 07:00AM  
Nov-06-19 09:08AM  
Oct-30-19 07:30AM  
Oct-20-19 08:57AM  
Oct-02-19 07:30AM  
Sep-17-19 07:30AM  
Aug-21-19 01:00PM  
Aug-13-19 07:30AM  
Aug-01-19 10:32AM  
Jun-23-19 10:30AM  
Jun-03-19 07:35AM  
May-24-19 07:35AM  
May-15-19 12:28PM  
May-06-19 10:30AM  
Apr-24-19 10:01AM  
Apr-18-19 08:00AM  
Apr-11-19 10:55AM  
Apr-10-19 08:24AM  
Apr-05-19 07:05AM  
Apr-04-19 09:57AM  
Apr-03-19 09:16AM  
Mar-18-19 07:30AM  
Mar-15-19 11:33AM  
Feb-27-19 07:00AM  
Feb-19-19 07:00AM  
Feb-11-19 07:00AM  
Jan-22-19 10:15PM  
Jan-16-19 07:00AM  
Jan-04-19 12:36PM  
Dec-03-18 07:00AM  
Nov-29-18 07:00AM  
Nov-09-18 08:00AM  
Nov-08-18 04:35PM  
Nov-05-18 10:30AM  
Nov-01-18 11:56AM  
Oct-22-18 07:00AM  
Oct-04-18 04:05PM  
Sep-25-18 07:00AM  
Sep-24-18 07:00AM  
Aug-09-18 04:05PM  
Aug-08-18 06:00PM  
Aug-07-18 01:20PM  
Aug-06-18 04:05PM  
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONWAY ROBERT EDirectorNov 19Buy8.0310,00080,30025,000Nov 23 05:00 PM